320 related articles for article (PubMed ID: 12145676)
1. Chronic myelogenous leukemia: mechanisms underlying disease progression.
Shet AS; Jahagirdar BN; Verfaillie CM
Leukemia; 2002 Aug; 16(8):1402-11. PubMed ID: 12145676
[TBL] [Abstract][Full Text] [Related]
2. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
[TBL] [Abstract][Full Text] [Related]
3. [Molecular pathogenesis of chronic myeloid leukemia].
Sasaki K; Mitani K
Nihon Rinsho; 2009 Oct; 67(10):1894-9. PubMed ID: 19860186
[TBL] [Abstract][Full Text] [Related]
4. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
[TBL] [Abstract][Full Text] [Related]
5. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
6. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.
Metzke-Heidemann S; Harder L; Gesk S; Schoch R; Jenisch S; Grote W; Siebert R; Schlegelberger B
Genes Chromosomes Cancer; 2001 May; 31(1):10-4. PubMed ID: 11284030
[TBL] [Abstract][Full Text] [Related]
7. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
8. The molecular biology of chronic myeloid leukaemia.
Melo JV
Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukaemia as a model of disease evolution in human cancer.
Melo JV; Barnes DJ
Nat Rev Cancer; 2007 Jun; 7(6):441-53. PubMed ID: 17522713
[TBL] [Abstract][Full Text] [Related]
10. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia.
Anastasi J; Feng J; Dickstein JI; Le Beau MM; Rubin CM; Larson RA; Rowley JD; Vardiman JW
Leukemia; 1996 May; 10(5):795-802. PubMed ID: 8656674
[TBL] [Abstract][Full Text] [Related]
11. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
[TBL] [Abstract][Full Text] [Related]
12. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
Okabe M
Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
[TBL] [Abstract][Full Text] [Related]
13. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.
Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S
Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of transformation by the BCR-ABL oncogene.
Sattler M; Griffin JD
Semin Hematol; 2003 Apr; 40(2 Suppl 2):4-10. PubMed ID: 12783368
[TBL] [Abstract][Full Text] [Related]
15. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
[TBL] [Abstract][Full Text] [Related]
16. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
[TBL] [Abstract][Full Text] [Related]
17. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
[TBL] [Abstract][Full Text] [Related]
18. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
19. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
[TBL] [Abstract][Full Text] [Related]
20. Chronic myelogenous leukemia molecular signature.
Nowicki MO; Pawlowski P; Fischer T; Hess G; Pawlowski T; Skorski T
Oncogene; 2003 Jun; 22(25):3952-63. PubMed ID: 12813469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]